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L E T T E R TO THE E D I T OR
Immunoglobulin replacement therapy for yellow nail syndrome
Dear Editor,
We read with interest the recent article from Gupta et al1
reporting innate and adaptive immunological alterations
occurring in patients with yellow nail syndrome (YNS).
The authors observed that immunoglobulin administration,
in the subset of YNS patients with immunoglobulin defi-
ciency, may result not only in decreased frequency and
severity of infections but also in an impressive effect on
lymphoedema and pleural effusion recurrence. They
described a single patient.1
Yellow nail syndrome has an estimated prevalence of
<1/1 000 000,2 and <400 patients have been reported in
the literature.3 YNS most often occurs in adults over
50 years, with no sex predominance.2-5 The etiopathogene-
sis is unclear although it has been related to impaired lym-
phatic and vascular drainage and with immunological
defects, including both T and B lymphocyte defects.1,4
Respiratory tract involvement may include unilateral or
bilateral pleural effusion(s), recurrent pneumonias,
bronchiectasis, chronic cough and chronic sinusitis.6 Lym-
phoedema may manifest many years after the nail changes.
YNS is a suggested paraneoplastic syndrome.3,7 Unfortu-
nately, there is no specific therapy for the disease. Symp-
tomatic relief, such as topic vitamin E and antifungal
therapy, has been proposed, without clear benefits.7
Here, we report the history of a 74-year-old patient pre-
senting with chronic cough, bronchiectasis, idiopathic
recurrent pleural effusion, thickened yellow nails associated
with pathological nail discoloration, lower limb lym-
phedema and immunoglobulin G deficiency. The examina-
tion revealed lower limb lymphoedema, especially below
the knees. His finger nails were dry, rigid and thickened
with brown vertical ridging; his toe nails were thickened,
yellow-pigmented and presented onycholysis (Figure 1). A
nail biopsy excluded onychomycosis and demonstrated
hyperpigmentation. Inflammatory and autoimmune markers
(erythrocyte sedimentation rate, C-reactive protein, ferritin,
antinuclear antibody, rheumatoid factor and antineutrophil
cytoplasmic antibody) were all negative. Proteinuria was
absent while total proteins, gammaglobulines and albumin
concentrations were reduced.
The patient had been referred for lymphoedema already
in 1993, 1 year after a trip in Guinea Bissau. The patient
was then investigated for filariasis and other tropical infec-
tive diseases, all with negative results. The patient further
reported high frequency and severity of respiratory
infections. Serum IgA and IgM concentrations were normal
while serum IgG levels were reduced (total IgG 420 mg/dL
with IgG-1 357 mg/dL and IgG-2 119 mg/dL). A computed
tomography of the chest showed bilateral pleural effusions
and bronchiectasis, predominantly in the lower lobes. Fluo-
rodeoxyglucose positron emission tomography (FDG-PET)
revealed no pulmonary FDG uptake. A thoracocentesis was
performed, and an analysis of pleural fluid revealed total
proteins 26 g/L, LDH 51 U/L, glucose 174 g/L, differential
leucocyte count 96/lL, polymorphonuclear cells 17% and
mononuclear cells 83%. The cytological and microbiological
examinations of pleural fluid were all negative. A pleural
biopsy showed unspecific chronic eosinophilic and lympho-
cytic inflammation associated with lymphoid aggregates of
the pleura. The patient was diagnosed with yellow nail syn-
drome based on the contemporary presence of the triade:
nail alterations, lymphoedema and pleural effusion. This tri-
ade is seen in one-third (27%-60%) of patients.8,9
After reading the article by Gupta et al,1 we decided to
treat the patient with monthly intravenous injections of
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immunoglobulin (IVIG), observing an early improvement
in YNS clinical manifestations. In particular, after the first
3 months of therapy, the lymphoedema and pleural effu-
sion stopped to worsen and the patient no longer required
pleural drainage or high dose of diuretics. IVIG treatment
also resulted in decreased frequency and severity of respi-
ratory infections, which previously had recurred every
3-4 weeks. A significant reduction in antibiotic use was
observed, which was associated with an increase in IgG
levels (total IgG 650 mg/dL). Until now, no improvements
in nail alterations were observed.
In conclusion, in selected patients with YNS, the intra-
venous immunoglobulin administration may be successfully
used to improve the clinical manifestations of this rare dis-
ease through a potential immunomodulatory effect poten-
tially associated with Fc receptors regulation, neutralization
of potential autoantibodies as well as inhibition of comple-
ment activation.
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